Skip to content

Functional evaluation of cholesterol level reduction in humans

Functional evaluation of cholesterol level reduction in humans - Functional evaluation of cholesterol level reduction in humans

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000048222
Enrollment
60
Registered
2022-07-04
Start date
2022-07-04
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adult

Interventions

Intake research food 3 tablets daily for 12 weeks Intake placebo 3 tablets daily for 12 weeks

Sponsors

EP Mediate Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Healthy male and female at the age of 20 to 64. (2) LDL cholesterol level at the time of pre-examination 2 test is 120 mg/dL or more and less than 140 mg/dL. (3) Triglyceride level at the time of pre-examination 2 is less than 150 mg/dL.

Exclusion criteria

Exclusion criteria: (1) Those who regularly intake foods, health foods, or medicines that are rich in active ingredients of research foods. (2) Those who are currently, or within the past 3 months have been, in the habit of continuously intaking foods with functional claims or health foods that claim to be related to lipid or glucose metabolism, or are planning to intake such foods during the study period. (3) Those with a history of dyslipidemia, hypertension, diabetes, psychiatric disorders, sleep disorders, or serious illnesses, or a history of continuous drug treatment. (4) Those with a BMI of 30 kg/m2 or higher. (5) Those who are at risk of developing allergies related to the research. (6) Those whose daily alcohol consumption exceeds an average of 60 g/day of pure alcohol equivalent. (7) Those who are judged to be unsuitable as a subject based on the results of the lifestyle questionnaire. (8) Those whose physical measurements, physical test values, and clinical test values before the start of ingestion show significant deviations from the standard range. (9) Those who are currently participating in other clinical tests, or those who have not passed 3 months after participation in other clinical tests. (10) Those who plan to become pregnant or breastfeed during the study period. (11) Those who are likely to change their lifestyle during the study period (e.g., long trips, etc.). (12) Any other person who is judged as inappropriate as a subject by the Chief Medical Officer.

Design outcomes

Primary

MeasureTime frame
LDL-cholesterol

Secondary

MeasureTime frame
Total cholesterol, HDL-cholesterol, LDL cholesterol-HDL cholesterol ratio, non-HDL cholesterol, Atherogenic index, triglycerides special clinical examination items (sd LDL cholesterol, oxidized LDL cholesterol, remnant-like lipoprotein-cholesterol)

Countries

Japan

Contacts

Public ContactKeiji Yamamoto

EP Mediate Co., Ltd. Foods Department, Trial Planning Section

yamamoto.keiji799@eps.co.jp070-3023-8214

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026